

Committed to Patients. Driven to Discover.

At Bristol Myers Squibb, we are driven by the discovery of science that may transform the lives of cancer patients.

Until we can meet again, please explore our oncology early stage disease pipeline below.



Oncology Early Stage Disease Pipeline

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. There is no guarantee that investigational agents or investigational uses will receive health authority approval or become commercially available in any country. Information as of March 2021.

	Modality	Area of Research	Phase
Breast			
⌘ Nivolumab + CDK inhibitor + aromatase inhibitor	Anti–PD-1 + CDK inhibitor + aromatase inhibitor	Neoadjuvant ER+/HER2- breast cancer	2
⌘ CDK inhibitor + aromatase inhibitor followed by nivolumab + CDK inhibitor + aromatase inhibitor	CDK inhibitor + aromatase inhibitor followed by anti–PD-1 + CDK inhibitor + aromatase inhibitor	Neoadjuvant ER+/HER2- breast cancer	2
⌘ Nivolumab + chemo followed by nivolumab + endocrine therapy	Anti–PD-1	Neoadjuvant/adjuvant high-risk breast cancer	3
Gastrointestinal			
Nivolumab	Anti–PD-1	Adjuvant esophageal or GEJ cancer	3
Nivolumab	Anti–PD-1	Adjuvant HCC	3
Genitourinary			
⌘ Nivolumab ± bempegaldesleukin (NKTR-214)	Anti–PD-1 ± CD122-biased IL-2 receptor	Peri-operative MIBC	3
⌘ Nivolumab + chemo ± linrodostat mesylate	Anti–PD-1 ± ID01 inhibitor	Peri-operative MIBC	3
Nivolumab	Anti–PD-1	Adjuvant invasive high-risk urothelial carcinoma	3
Nivolumab ± ipilimumab	Anti–PD-1 ± anti–CTLA-4	Adjuvant RCC	3
Lung			
⌘ Neoadjuvant nivolumab + chemo, followed by adjuvant nivolumab	Anti–PD-1	Resectable stage II-IIIB NSCLC (≥4cm)	3
⌘ Neoadjuvant nivolumab + chemo	Anti–PD-1	Resectable stage IB-IIIA NSCLC (≥4cm)	3
Melanoma			
Nivolumab	Anti–PD-1	Adjuvant fully resected stage IIB/C melanoma	3
⌘ Nivolumab ± bempegaldesleukin (NKTR-214)	Anti–PD-1 ± CD122-preferential IL-2 pathway agonist	Adjuvant fully resected melanoma in patients at high risk for recurrence	3

⌘ = Trial investigates BMS agent(s) in combination with 1 or more non–BMS-owned assets. Development partnerships include:

- Bempegaldesleukin: Nektar

CDK=cyclin-dependent kinase; chemo=chemotherapy; CTLA-4=cytotoxic T-lymphocyte antigen 4; ER=estrogen receptor; ID01=indoleamine 2,3- deoxygenate-1; GEJ=gastroesophageal junction; HCC=hepatocellular carcinoma; HER2=human epidermal growth factor receptor 2; IL-2=interleukin-2; MIBC=muscle-invasive bladder cancer; RCC=renal cell carcinoma; NSCLC=non–small cell lung cancer; PD-1=programmed death receptor-1